{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T13:39:12Z","timestamp":1770471552736,"version":"3.49.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The Hyperhidrosis Quality of Life Index (HidroQoL\u00a9) is a well-developed patient-reported outcome measure assessing the quality of life impacts in hyperhidrosis (HH), which has proven very good measurement properties, such as structural validity and internal consistency.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We aimed to investigate responsiveness over time and estimate values for meaningful within-person change (MWPC) towards symptom improvement for different measurement timepoints (4 and 12 weeks), extending the existing validity evidence in patients with primary axillary HH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data (from a phase IIIb clinical trial) were collected at baseline, and at weeks 4, 8, 12, 28, 52 and 72. For the assessment of responsiveness, HidroQoL change scores were correlated with corresponding change scores of the Hyperhidrosis Disease Severity Scale (HDSS), the Dermatology Life Quality Index (DLQI) and gravimetric sweat production based on a priori formulated hypotheses. Furthermore, we tested whether the different HDSS change score groups differed significantly from each other over time and whether the HidroQoL was sensitive towards these group differences over time. This was extended by the calculation of matched-pair tests and effect sizes to test significance for each change group separately. For the estimation of MWPC thresholds towards symptom improvement, different anchor-based and integrated approaches were used.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, the sample comprised 357 patients with primary axillary HH. For the assessment of responsiveness, five out of 14 a priori hypotheses regarding the correlation of the change scores could be confirmed, whereas the rejected hypotheses differed only marginally from the expected values. Furthermore, regarding responsiveness, the HidroQoL showed sensitivity towards symptom improvement at each measurement timepoint. Effect sizes were large as expected (d \u2265 0.806). MWPC thresholds towards symptom improvement were proposed for two measurement timepoints: 5 (week 4) and 6 (week 12). Increasing MWPC values over time were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study extends the evidence for the longitudinal validity of the HidroQoL\u00a9 up to 72 weeks and proposed MWPC thresholds for different time intervals (4 and 12 weeks) after baseline, aiding interpretability. Results concur with findings from previous validation studies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae415","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T22:51:01Z","timestamp":1730155861000},"page":"450-457","source":"Crossref","is-referenced-by-count":2,"title":["Longitudinal validity of the Hyperhidrosis Quality of Life Index (HidroQoL\u00a9) in a phase IIIb clinical trial population with hyperhidrosis: responsiveness and meaningful change"],"prefix":"10.1093","volume":"192","author":[{"given":"Theresa","family":"Donhauser","sequence":"first","affiliation":[{"name":"Institute of Social Medicine and Health Systems Research, Otto-von-Guericke University Magdeburg , Magdeburg ,","place":["Germany"]},{"name":"University of Regensburg , Regensburg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-7549","authenticated-orcid":false,"given":"Michaela","family":"Gabes","sequence":"additional","affiliation":[{"name":"Institute of Social Medicine and Health Systems Research, Otto-von-Guericke University Magdeburg , Magdeburg ,","place":["Germany"]},{"name":"University of Regensburg , Regensburg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-727X","authenticated-orcid":false,"given":"Clarissa","family":"Masur","sequence":"additional","affiliation":[{"name":"Dr. August Wolff GmbH & Co. KG Arzneimittel , Bielefeld ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Kamudoni","sequence":"additional","affiliation":[{"name":"Darmstadt , German"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Salek","sequence":"additional","affiliation":[{"name":"School of Life and Medical Sciences, University of Hertfordshire ,","place":["UK"]},{"name":"Institute of Medicines Development , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Abels","sequence":"additional","affiliation":[{"name":"Dr. August Wolff GmbH & Co. KG Arzneimittel , Bielefeld ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3805-8219","authenticated-orcid":false,"given":"Christian","family":"Apfelbacher","sequence":"additional","affiliation":[{"name":"Institute of Social Medicine and Health Systems Research, Otto-von-Guericke University Magdeburg , Magdeburg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"2025021810043529100_ljae415-B1","doi-asserted-by":"crossref","first-page":"f6800","DOI":"10.1136\/bmj.f6800","article-title":"Diagnosis and management of hyperhidrosis","volume":"347","author":"Benson","year":"2013","journal-title":"BMJ"},{"key":"2025021810043529100_ljae415-B2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0733-8635(05)70062-0","article-title":"Treatment of hyperhidrosis","volume":"16","author":"Stolman","year":"1998","journal-title":"Dermatologic Clin"},{"key":"2025021810043529100_ljae415-B3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s13555-022-00885-w","article-title":"Hyperhidrosis: a central nervous dysfunction of sweat secretion","volume":"13","author":"Wohlrab","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025021810043529100_ljae415-B4","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00403-016-1697-9","article-title":"Hyperhidrosis: an update on prevalence and severity in the United States","volume":"308","author":"Doolittle","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"2025021810043529100_ljae415-B5","volume-title":"Development, Validation and Clinical Application of a Patient-Reported Outcome Measure in Hyperhidrosis: The Hyperhidrosis Quality of Life Index (HidroQoL\u00a9)","author":"Kamudoni","year":"2014"},{"key":"2025021810043529100_ljae415-B6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11136-014-0825-2","article-title":"The development and validation of a disease-specific quality of life measure in hyperhidrosis: the Hyperhidrosis Quality of Life Index (HidroQoL\u00a9)","volume":"24","author":"Kamudoni","year":"2015","journal-title":"Qual Life Res"},{"key":"2025021810043529100_ljae415-B7","first-page":"1","article-title":"Measurement properties of patient-reported outcome measures (PROMs) in hyperhidrosis: a systematic review","author":"Gabes","year":"2021","journal-title":"Qual Life Res"},{"key":"2025021810043529100_ljae415-B8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bjd.19300","article-title":"Hyperhidrosis Quality of Life Index (HidroQoL\u00a9): further validation and clinical application in patients with axillary hyperhidrosis using data from a phase III randomized controlled trial","volume":"184","author":"Gabes","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025021810043529100_ljae415-B9","volume-title":"COSMIN methodology for systematic reviews of patient-reported outcome measures (PROMs); user manual; version 1.0","author":"Mokkink","year":"2018"},{"key":"2025021810043529100_ljae415-B10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","article-title":"COSMIN guideline for systematic reviews of patient-reported outcome measures","volume":"27","author":"Prinsen","year":"2018","journal-title":"Qual Life Res"},{"key":"2025021810043529100_ljae415-B11","first-page":"15","article-title":"Patient-focused drug development (PFDD) guidance public workshop: methods to identify what is important to patients & select, develop or modify fit-for purpose clinical outcomes assessments","author":"US Food and Drug Administration"},{"key":"2025021810043529100_ljae415-B12","first-page":"229","article-title":"Safety and efficacy of topical formulations containing 0.5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study","volume":"182","author":"Masur","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025021810043529100_ljae415-B13","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s11136-021-02822-4","article-title":"COSMIN reporting guideline for studies on measurement properties of patient-reported outcome measures","volume":"30","author":"Gagnier","year":"2021","journal-title":"Qual Life Res"},{"key":"2025021810043529100_ljae415-B14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1023499322593","article-title":"On assessing responsiveness of health-related quality of life instruments: guidelines for instrument evaluation","volume":"12","author":"Terwee","year":"2003","journal-title":"Qual Life Res"},{"key":"2025021810043529100_ljae415-B15","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/jdv.18843","article-title":"Long-term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: results from a phase 3b trial","volume":"37","author":"Szeimies","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025021810043529100_ljae415-B16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bjd.19810","article-title":"A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial","volume":"185","author":"Abels","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025021810043529100_ljae415-B17","doi-asserted-by":"crossref","first-page":"700","DOI":"10.5114\/ada.2019.84227","article-title":"Differences in subjective and objective evaluation of hyperhidrosis. Study among medical students","volume":"37","author":"Dobosz","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"2025021810043529100_ljae415-B18","volume-title":"Measurement in Medicine: A Practical Guide, 10th printing (first published 2011). Series: Practical Guides to Biostatistics and Epidemiology","author":"Vet HCW","year":"2018"},{"key":"2025021810043529100_ljae415-B19","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-10-8414-0","volume-title":"Living with Chronic Disease: Measuring Important Patient-Reported Outcomes","author":"Kamudoni","year":"2018"},{"key":"2025021810043529100_ljae415-B20","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bjd.18204","article-title":"Evaluation of responsiveness and estimation of smallest detectable change and minimal important change scores for the Childhood Atopic Dermatitis Impact Scale","volume":"182","author":"Gabes","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025021810043529100_ljae415-B21","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1007\/978-94-007-0753-5_2465","volume-title":"Encyclopedia of Quality of Life and Well-Being Research","author":"Guhn","year":"2014"},{"key":"2025021810043529100_ljae415-B22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0005-7894(84)80002-7","article-title":"Psychotherapy outcome research: methods for reporting variability and evaluating clinical significance","volume":"15","author":"Jacobson","year":"1984","journal-title":"Behavior Ther"},{"key":"2025021810043529100_ljae415-B23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"key":"2025021810043529100_ljae415-B24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"key":"2025021810043529100_ljae415-B25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.thorsurg.2008.01.002","article-title":"Evaluating the patient presenting with hyperhidrosis","volume":"18","author":"Solish","year":"2008","journal-title":"Thorac Surg Clin"},{"key":"2025021810043529100_ljae415-B26","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1016\/j.jval.2022.09.1972","article-title":"PCR37 Understanding symptoms and meaningful change in patient global impression scales for patients with advanced\/metastatic non-small cell lung cancer (adv\/met NSCLC): a qualitative research study","volume":"25","author":"Kelly","year":"2022","journal-title":"Value Health"},{"key":"2025021810043529100_ljae415-B27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12955-017-0693-x","article-title":"The impact of hyperhidrosis on patients\u2019 daily life and quality of life: a qualitative investigation","volume":"15","author":"Kamudoni","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"2025021810043529100_ljae415-B28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11136-006-9109-9","article-title":"Minimally important change determined by a visual method integrating an anchor-based and a distribution-based approach","volume":"16","author":"Vet HCW","year":"2007","journal-title":"Qual Life Res"},{"key":"2025021810043529100_ljae415-B29","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s11136-021-02925-y","article-title":"Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures","volume":"30","author":"Terwee","year":"2021","journal-title":"Qual Life Res"},{"key":"2025021810043529100_ljae415-B30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","article-title":"Quality criteria were proposed for measurement properties of health status questionnaires","volume":"60","author":"Terwee","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"2025021810043529100_ljae415-B31","doi-asserted-by":"crossref","DOI":"10.4324\/9780203771587","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"2013"},{"key":"2025021810043529100_ljae415-B32","article-title":"StatistikGuru: Cohen\u2019s d berechnen","author":"Hemmerich"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae415\/60934283\/ljae415.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/3\/450\/60934283\/ljae415.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/3\/450\/60934283\/ljae415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T10:05:17Z","timestamp":1739873117000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/3\/450\/7848193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10,28]]},"published-print":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae415","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,10,28]]}}}